Growth inhibitory concentrations of androgens up-regulate insulin-like growth factor binding protein-3 expression via an androgen response element in LNCaP human prostate cancer cells

Endocrinology

Volumn 147, Issue 10, 2006, Pages 4599-4607

  Peng, Lihong ^a   Malloy, Peter J ^a   Wang, Jining ^a   Feldman, David ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROSTANOLONE; BICALUTAMIDE; CALCITRIOL; METRIBOLONE; PROTEIN P21; PROTEIN P27; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE; CELL GROWTH; CELL STRAIN LNCAP; CONTROLLED STUDY; DOSE RESPONSE; DRUG INHIBITION; GEL MOBILITY SHIFT ASSAY; HORMONE RESPONSIVE ELEMENT; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; POINT MUTATION; PRIORITY JOURNAL; PROSTATE CANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANDROGENS; BLOTTING, WESTERN; CALCITRIOL; CALCIUM CHANNEL AGONISTS; CELL LINE, TUMOR; CHROMATIN; ELECTROPHORETIC MOBILITY SHIFT ASSAY; FLOW CYTOMETRY; GROWTH; HUMANS; IMMUNOPRECIPITATION; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; MALE; PLASMIDS; PROMOTER REGIONS (GENETICS); PROSTATIC NEOPLASMS; RESPONSE ELEMENTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSFECTION; UP-REGULATION;

EID: 33748748130     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2006-0560     Document Type: Article

References (65)

1. Hwa V, Oh Y, Rosenfeld RG 1999 The insulin-like growth factor-binding protein (IGFBP) superfamily. Endocr Rev 20:761-787
2. Firth SM, Baxter RC 2002 Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 23:824-854
3. Cohen P 2006 Insulin-like growth factor binding protein-3: insulin-like growth factor independence comes of age. Endocrinology 147:2109-2111
4. Rajah R, Valentinis B, Cohen P 1997 Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-β1 on programmed cell death through a p53- and IGF-independent mechanism. J Biol Chem 272:12181-12188
5. Rajah R, Khare A, Lee PD, Cohen P 1999 Insulin-like growth factor-binding protein-3 is partially responsible for high-serum-induced apoptosis in PC-3 prostate cancer cells. J Endocrinol 163:487-494
6. Kim HS, Ingermann AR, Tsubaki J, Twigg SM, Walker GE, Oh Y 2004 Insulin-like growth factor-binding protein 3 induces caspase-dependent apoptosis through a death receptor-mediated pathway in MCF-7 human breast cancer cells. Cancer Res 64:2229-2237
7. Santer FR, Bacher N, Moser B, Morandell, D, Ressler S, Firth SM, Spoden GA, Sergi C, Baxter RC, Jansen-Durr P, Zwerschke W 2006 Nuclear insulin-like growth factor binding protein-3 induces apoptosis and is targeted to ubiquitin/proteasome-dependent proteolysis. Cancer Res 66:3024-3033
8. Leal SM, Liu Q, Huang SS, Huang JS 1997 The type V transforming growth factor β receptor is the putative insulin-like growth factor-binding protein 3 receptor. J Biol Chem 272:20572-20576
9. Schedlich LJ, Le Page SL, Firth SM, Briggs LJ, Jans DA, Baxter RC 2000 Nuclear import of insulin-like growth factor-binding protein-3 and -5 is mediated by the importin β subunit. J Biol Chem 275:23462-23470
10. Liu B, Lee HY, Weinzimer SA, Powell DR, Clifford JL, Kurie JM, Cohen P 2000 Direct functional interactions between insulin-like growth factor-binding protein-3 and retinoid X receptor-α regulate transcriptional signaling and apoptosis. J Biol Chem 275:33607-33613
11. Chokkalingam AP, Pollak M, Fillmore CM, Gao YT, Stanczyk FZ, Deng J, Sesterhenn IA, Mostofi FK, Fears TR, Madigan MP, Ziegler RG, Fraumeni JF, Hsing AW 2001 Insulin-like growth factors and prostate cancer: a population-based case-control study in China. Cancer Epidemiol Biomarkers Prev 10:421-427
12. Shi R, Berkel HJ, Yu H 2001 Insulin-like growth factor-I and prostate cancer: a meta-analysis. Br J Cancer 85:991-996
13. Chan JM, Stampfer MJ, Ma J, Gann P, Gaziano JM, Pollak M, Giovannucci E 2002 Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J Natl Cancer Inst 94:1099-1106
14. Oh Y, Gucev Z, Ng L, Muller HL, Rosenfeld RG 1995 Antiproliferative actions of insulin-like growth factor binding protein (IGFBP)-3 in human breast cancer cells. Prog Growth Factor Res 6:503-512
15. Valentinis B, Bhala A, DeAngelis T, Baserga R, Cohen P 1995 The human insulin-like growth factor (IGF) binding protein-3 inhibits the growth of fibroblasts with a targeted disruption of the IGF-I receptor gene. Mol Endocrinol 9:361-367
16. Hong J, Zhang G, Dong F, Rechler MM 2002 Insulin-like growth factor (IGF)-binding protein-3 mutants that do not bind IGF-I or IGF-II stimulate apoptosis in human prostate cancer cells. J Biol Chem 277:10489-10497
17. Liu B, Lee KW, Li H, Ma l, Lin GL, Chandraratna RA, Cohen P 2005 Combination therapy of insulin-like growth factor binding protein-3 and retinoid X receptor ligands synergize on prostate cancer cell apoptosis in vitro and in vivo. Clin Cancer Res 11:4851-4856
18. Silha JV, Sheppard PC, Mishra S, Gui Y, Schwartz J, Dodd JG, Murphy LJ 2006 Insulin-like growth factor (IGF) binding protein-3 attenuates prostate tumor growth by IGF-dependent and IGF-independent mechanisms. Endocrinology 147:2112-2121
19. Ali O, Cohen P, Lee KW 2003 Epidemiology and biology of insulin-like growth factor binding protein-3 (IGFBP-3) as an anti-cancer molecule. Horm Metab Res 35:726-733
20. Boyle BJ, Zhao XY, Cohen P, Feldman D 2001 Insulin-like growth factor binding protein-3 mediates 1α,25-dihydroxyvitamin d(3) growth inhibition in the LNCaP prostate cancer cell line through p21/WAF1. J Urol 165:1319-1324
21. Peng L, Malloy PJ, Feldman D 2004 Identification of a functional vitamin D response element in the human insulin-like growth factor binding protein-3 promoter. Mol Endocrinol 18:1109-1119
22. Buckbinder L, Talbott R, Velasco-Miguel S, Takenaka I, Faha B, Seizinger BR, Kley N 1995 Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 377:646-649
23. Goossens K, Esquenet M, Swinnen JV, Manin M, Rombauts W, Verhoeven G 1999 Androgens decrease and retinoids increase the expression of insulin-like growth factor-binding protein-3 in LNcaP prostatic adenocarcinoma cells. Mol Cell Endocrinol 155:9-18
24. Martin JL, Pattison SL 2000 Insulin-like growth factor binding protein-3 is regulated by dihydrotestosterone and stimulates deoxyribonucleic acid synthesis and cell proliferation in LNCaP prostate carcinoma cells. Endocrinology 141:2401-2409
25. Arnold JT, Le H, McFann KK, Blackman MR 2005 Comparative effects of DHEAvs. testosterone, dihydrotestosterone, and estradiol on proliferation and gene expression in human LNCaP prostate cancer cells. Am J Physiol Endocrinol Metab 288:E573-E584
26. Murthy S, Agoulnik IU, Weigel NL 2005 Androgen receptor signaling and vitamin D receptor action in prostate cancer cells. Prostate 64:362-372
27. Kojima S, Mulholland DJ, Ettinger S, Fazli L, Nelson CC, Gleave ME 2006 Differential regulation of IGFBP-3 by the androgen receptor in the lineage-related androgen-dependent LNCaP and androgen-independent C4-2 prostate cancer models. Prostate 66:971-986
28. Gelmann EP 2002 Molecular biology of the androgen receptor. J Clin Oncol 20:3001-3015
29. Hellerstedt BA, Pienta KJ 2002 The current state of hormonal therapy for prostate cancer. CA Cancer J Clin 52:154-179
30. Nelson WG, De Marzo AM, Isaacs WB 2003 Prostate cancer. N Engl J Med 349:366-381
31. Culig Z, Steiner H, Bartsch G, Hobisch A 2005 Mechanisms of endocrine therapy-responsive and unresponsive prostate tumours. Endocr Relat Cancer 12:229-244
32. Bruchovsky N, Lesser B, Van Doorn E, Craven S 1975 Hormonal effects on cell proliferation in rat prostate. Vitam Horm 33:61-102
33. Sonnenschein C, Olea N, Pasanen ME, Soto AM 1989 Negative controls of cell proliferation: human prostate cancer cells and androgens. Cancer Res 49:3474-3481
34. Olea N, Sakabe K, Soto AM, Sonnenschein C 1990 The proliferative effect of "anti-androgens" on the androgen-sensitive human prostate tumor cell line LNCaP. Endocrinology 126:1457-1463
35. Umekita Y, Hiipakka RA, Kokontis JM, Liao S 1996 Human prostate tumor growth in athymic mice: inhibition by androgens and stimulation by finasteride. Proc Natl Acad Sci USA 93:11802-11807
36. Joly-Pharaboz M, Ruffion A, Roch A, Michel-Calemard L, Andre J, Chantepie J, Nicolas B, Panaye G 2000 Inhibition of growth and induction of apoptosis by androgens of a variant of LNCaP cell line. J Steroid Biochem Mol Biol 73:237-249
37. Chuu CP, Hiipakka RA, Fukuchi J, Kokontis JM, Liao S 2005 Androgen causes growth suppression and reversion of androgen-independent prostate cancer xenografts to an androgen-stimulated phenotype in athymic mice. Cancer Res 65:2082-2084
38. Lee C, Sutkowski DM, Sensibar JA, Zelner D, Kim Z, Amsel I, Shaw N, Prins GS, Kozlowski JM 1995 Regulation of proliferation and production of prostate-specific antigen in androgen-sensitive prostatic cancer cells, LNCaP, by dihydrotestosterone. Endocrinology 136:796-803
39. Esquenet M, Swinnen JV, Heyns W, Verhoeven G 1996 Control of LNCaP proliferation and differentiation: actions and interactions of androgens, 1α,25-dihydroxycholecalciferol, all-trans retinoic acid, 9-cis retinoic acid, and phenylacetate. Prostate 28:182-194
40. Zhao XY, Ly LH, Peehl DM, Feldman D 1997 1α,25-dihydroxyvitamin D3 actions in LNCaP human prostate cancer cells are androgen-dependent. Endocrinology 138:3290-3298
41. Verrijdt G, Haelens A, Claessens F 2003 Selective DNA recognition by the androgen receptor as a mechanism for hormone-specific regulation of gene expression. Mol Genet Metab 78:175-185
42. Burton K 1956 A study of the conditions and mechanism of the diphenylamine reaction for the colorimetric estimation of deoxyribonucleic acid. Biochem J 62:315-323
43. Husbeck B, Nonn L, Peehl DM, Knox SJ 2006 Tumor-selective killing by selenite in patient-matched pairs of normal and malignant prostate cells. Prostate 66:218-225
44. Livak KJ, Schmittgen TD 2001 Analysis of relative gene expression data using real-time quantitative PCR and the 2[-ΔΔC(T)] method. Methods 25:402-408
45. Peng L, Payne AH 2002 AP-2γ and the homeodomain protein distal-less 3 are required for placental-specific expression of the murine 3β-hydroxysteroid dehydrogenase VI gene, Hsd3b6. J Biol Chem 277:7945-7954
46. Deryckere F, Gannon F 1994 A one-hour minipreparation technique for extraction of DNA-binding proteins from animal tissues. Biotechniques 16:405
47. Ikezoe T, Chen SS, Yang Y, Heber D, Taguchi H, Koeffler HP 2003 PC-SPES: Molecular mechanism to induce apoptosis and down-regulate expression of PSA in LNCaP human prostate cancer cells. Int J Oncol 23:1461-1470
48. de Launoit Y, Veilleux R, Dufour M, Simard J, Labrie F 1991 Characteristics of the biphasic action of androgens and of the potent antiproliferative effects of the new pure antiestrogen EM-139 on cell cycle kinetic parameters in LNCaP human prostatic cancer cells. Cancer Res 51:5165-5170
49. Lu S, Liu M, Epner DE, Tsai SY, Tsai MJ 1999 Androgen regulation of the cyclin-dependent kinase inhibitor p21 gene through an androgen response element in the proximal promoter. Mol Endocrinol 13:376-384
50. Hofman K, Swinnen JV, Verhoeven G, Heyns W 2001 E2F activity is biphasically regulated by androgens in LNCaP cells. Biochem Biophys Res Commun 283:97-101
51. Verrijdt G, Schoenmakers E, Alen P, Haelens A, Peeters B, Rombauts W, Claessens F 1999 Androgen specificity of a response unit upstream of the human secretory component gene is mediated by differential receptor binding to an essential androgen response element. Mol Endocrinol 13:1558-1570
52. Claessens F, Verrijdt G, Schoenmakers E, Haelens A, Peeters B, Verhoeven G, Rombautws W 2001 Selective DNA binding by the androgen receptor as a mechanism for hormone-specific gene regulation. J Steroid Biochem Mol Biol 7:23-30
53. Rennie PS, Bruchovsky N, Leco KJ, Sheppard PC, McQueen SA, Cheng H, Snoek R, Hamel A, Bock ME, MacDonald BS, Nickel BE, Chang C, Liao S, Cattini PA, Matusik RJ 1993 Characterization of two cis-acting DNA elements involved in the androgen regulation of the probasin gene. Mol Endocrinol 7:23-36
54. Tsai MJ, O'Malley BW 1994 Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu Rev Biochem 63:451-486
55. Oh Y, Muller HL, Ng L, Rosenfeld RG 1995 Transforming growth factor-β-induced cell growth inhibition in human breast cancer cells is mediated through insulin-like growth factor-binding protein-3 action. J Biol Chem 270:13589-13592
56. Gucev ZS, Oh Y, Kelley KM, Rosenfeld RG 1996 Insulin-like growth factor binding protein 3 mediates retinoic acid- and transforming growth factor β2-induced growth inhibition in human breast cancer cells. Cancer Res 56:1545-1550
57. Colston KW, Perks CM, Xie SP, Holly JM 1998 Growth inhibition of both MCF-7 and Hs578T human breast cancer cell lines by vitamin D analogues is associated with increased expression of insulin-like growth factor binding protein-3. J Mol Endocrinol 20:157-162
58. Rozen F, Zhang J, Pollak M 1998 Antiproliferative action of tumor necrosis factor-α on MCF-7 breast cancer cells is associated with increased insulin-like growth factor binding protein-3 accumulation. Int J Oncol 13:865-869
59. Tsubaki J, Choi WK, Ingermann AR, Twigg SM, Kim HS, Rosenfeld RG, Oh Y 2001 Effects of sodium butyrate on expression of members of the IGF-binding protein superfamily in human mammary epithelial cells. J Endocrinol 169:97-110
60. Krishnan AV, Peehl DM, Feldman D 2005 Vitamin D and prostate cancer. In: Feldman D, Pike JW, Glorieux FH, ed. Vitamin D. San Diego: Elsevier Academic Press; 1679-1707
61. Stewart LV, Weigel NL 2005 Role of insulin-like growth factor binding proteins in 1α,25-dihydroxyvitamin D(3)-induced growth inhibition of human prostate cancer cells. Prostate 64:9-19
62. Moffatt KA, Johannes WU, Hedlund TE, Miller GJ 2001 Growth inhibitory effects of 1α, 25-dihydroxyvitamin D(3) are mediated by increased levels of p21 in the prostatic carcinoma cell line ALVA-31. Cancer Res 61:7122-7129
63. Zhao XY, Peehl DM, Navone NM, Feldman D 2000 1α,25-Dihydroxyvitamin D3 inhibits prostate cancer cell growth by androgen-dependent and androgen-independent mechanisms. Endocrinology 141:2548-2556
64. DeMarzo AM, Nelson WG, Isaacs WB, Epstein JI 2003 Pathological and molecular aspects of prostate cancer. Lancet 361:955-964
65. Hendriksen PJ, Dits NF, Kokame K, Veldhoven A, van Weerden WM, Bangma CH, Trapman J, Jenster G 2006 Evolution of the androgen receptor pathway during progression of prostate cancer. Cancer Res 66:5012-5020